A Proposal for a Simple Subclassification of Advanced Hepatocellular Carcinoma in Systemic Treatment DOI Open Access
Norihiro Imai, Takafumi Yamamoto, Kazuyuki Mizuno

и другие.

Cancers, Год журнала: 2024, Номер 16(22), С. 3797 - 3797

Опубликована: Ноя. 12, 2024

Objectives: This study focused on the presence or absence of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma (HCC) examined their impact systemic treatment outcomes. Methods: We retrospectively analyzed 362 patients with unresectable HCC who received first-line therapy. The prognostic evaluation was based at time initiation. Results: Patients (advanced group) had significantly worse outcomes than those without these features (intermediate group), median survival times 434 658 days, respectively. Further subdivision advanced group into three categories—patients only (m group, n = 77), (v 78), both (vm 52)—revealed that m better other two groups, 649, 323, 187 A comparison clinical backgrounds among groups demonstrated liver function initiation groups. Multivariable analysis, including performance status, Child–Pugh score, use immune checkpoint inhibitors as therapy, identified an independent significant factor (hazard ratio, 0.50). Conclusions: Unresectable no represents a novel staging category for treatment.

Язык: Английский

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study DOI Creative Commons

Junfeng Bu,

Zihan Li,

Die Hu

и другие.

Frontiers in Oncology, Год журнала: 2025, Номер 15

Опубликована: Фев. 25, 2025

Unresectable hepatocellular carcinoma (HCC) presents significant treatment challenges. While locoregional therapies (LT) and tyrosine kinase inhibitors (TKI) offer some benefits, prognosis remains poor. Immune checkpoint (ICI) have shown promise in other oncological settings, suggesting potential benefits HCC regimens. This retrospective study analyzed 232 patients diagnosed with unresectable at West China Hospital from January 2019 to December 2023. Patients were categorized into two groups: LT+TKI LT+TKI+ICI. All underwent standardized treatments first-line TKIs, the latter group also receiving ICIs. The primary endpoints measured overall survival (OS) progression-free (PFS). Survival analysis utilized Kaplan-Meier estimates Cox regression models. LT+TKI+ICI demonstrated significantly improved outcomes compared group. Median OS was 28 ± 3.9 months versus 21 3.0 group, corresponding 6-, 12-, 24-month rates of 96.8%, 79.3%, 59.4% 85.8%, 71.5%, 44.1%, respectively (HR, 0.64; 95% CI, 0.449-0.913; P = 0.014). PFS favored (11 1.1 vs. 7 0.76 months; HR, 0.60; 0.452-0.805; P<0.001). Multivariable identified LT+TKI, vascular invasion, metastasis as independent risk factors for poorer outcomes. Adding ICI LT TKI extends both HCC. These findings suggest that integrating protocols could be beneficial managing HCC, particularly invasion.

Язык: Английский

Процитировано

0
Targeting TIME in Advanced Hepatocellular Carcinoma: Mechanisms of Drug Resistance and Treatment Strategies DOI
Xinyi Ye, Xizhu Fang, Fangfang Li

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер unknown, С. 104735 - 104735

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Treatment options for advanced hepatocellular carcinoma: the potential of biologics DOI
Federico Rossari,

Silvia Foti,

S. Camera

и другие.

Expert Opinion on Biological Therapy, Год журнала: 2024, Номер 24(6), С. 455 - 470

Опубликована: Июнь 2, 2024

Introduction Advanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovative therapeutic regimens and approaches, especially immune-based, remain to be explored aiming at extending benefits wider population patients.

Язык: Английский

Процитировано

2
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results DOI
Leonardo Stella, Clémence Hollande,

Yasmina Ben Merabet

и другие.

Expert Opinion on Emerging Drugs, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 15, 2024

Introduction Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a significant cause of cancer-related morbidity mortality. Limited treatment options for advanced stages emphasize need effective therapies.

Язык: Английский

Процитировано

1
A Proposal for a Simple Subclassification of Advanced Hepatocellular Carcinoma in Systemic Treatment DOI Open Access
Norihiro Imai, Takafumi Yamamoto, Kazuyuki Mizuno

и другие.

Cancers, Год журнала: 2024, Номер 16(22), С. 3797 - 3797

Опубликована: Ноя. 12, 2024

Objectives: This study focused on the presence or absence of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma (HCC) examined their impact systemic treatment outcomes. Methods: We retrospectively analyzed 362 patients with unresectable HCC who received first-line therapy. The prognostic evaluation was based at time initiation. Results: Patients (advanced group) had significantly worse outcomes than those without these features (intermediate group), median survival times 434 658 days, respectively. Further subdivision advanced group into three categories—patients only (m group, n = 77), (v 78), both (vm 52)—revealed that m better other two groups, 649, 323, 187 A comparison clinical backgrounds among groups demonstrated liver function initiation groups. Multivariable analysis, including performance status, Child–Pugh score, use immune checkpoint inhibitors as therapy, identified an independent significant factor (hazard ratio, 0.50). Conclusions: Unresectable no represents a novel staging category for treatment.

Язык: Английский

Процитировано

0